Tango Therapeutics, Inc. (TNGX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Tango Therapeutics is a precision oncology company focused on developing novel drugs for genetically defined cancers. The company has no approved products and has not generated revenue from product sales. Its primary pipeline includes vopimetostat (TNG462), a PRMT5 inhibitor for non-CNS cancers, and TNG456, a brain-penetrant PRMT5 inhibitor for CNS cancers.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Collaboration Revenue | $0 | $3,181 | $0 | $8,573 |
| Net Loss | $(55,341) | $(38,853) | $(100,856) | $(78,729) |
| Net Loss Per Share | $(0.37) | $(0.35) | $(0.68) | $(0.71) |
| Operating Expenses | $59,785 | $44,148 | $108,555 | $92,070 |
| Cash & Marketable Securities | $1.01 billion (as of June 30, 2026) | |||
| Accumulated Deficit | $(704.0 million) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Cessation: Collaboration revenue dropped to zero in Q2 2026 compared to $3.2 million in Q2 2025. This is due to the conclusion of the research portion of the Gilead collaboration agreement in August 2025, which resulted in the recognition of all remaining deferred revenue in Q3 2025.
- Increased Operating Expenses: Total operating expenses increased by 35% year-over-year for the quarter ($59.8M vs $44.1M). This was driven by a $4.4M increase in R&D (advancement of vopimetostat and TNG456) and an $11.2M increase in G&A (personnel costs and stock-based compensation).
- Capital Raise: In June 2026, the company completed an underwritten offering raising $651.4 million in net proceeds. This significantly bolstered liquidity, increasing cash and marketable securities from $343M at year-end 2025 to over $1 billion.
- Portfolio Deprioritization: The company announced the deprioritization of TNG260 and TNG961 in May 2026 due to limited clinical benefit or strategic realignment, reducing future costs for these programs.
Guidance, Outlook, and Risks
- Clinical Milestones:
- vopimetostat + RAS Inhibitors: Reported strong initial data in PDAC (92% ORR with daraxonrasib; 52% ORR with zoldonrasib). Plans to advance to Phase 3 for MTAP-deleted pancreatic cancer.
- TNG456: Anticipates initial clinical data in the second half of 2026.
- New Combination: Plans to initiate a Phase 1/2 trial of vopimetostat with Erasca's ERAS-0015 in the second half of 2026.
- Liquidity: Management expects existing cash and marketable securities ($1.0 billion) to fund operations for at least the next 12 months.
- Key Risks:
- Supply Chain: Reliance on WuXi AppTec as the sole source of API for clinical-stage candidates, subject to potential U.S. legislative restrictions (BIOSECURE Act).
- Development Risk: No products approved; clinical trials may fail to demonstrate efficacy or safety.
- Capital Needs: Continued need for substantial additional funding to support operations and development.
Investor Verification Checklist
- Capital Runway: Verify the burn rate against the $1.0 billion cash balance to confirm the 12-month liquidity runway.
- Supply Chain Exposure: Assess the impact of the BIOSECURE Act on the company's reliance on WuXi AppTec for API supply.
- Clinical Data Durability: Monitor upcoming data readouts for vopimetostat combinations (ESMO 2026) to validate the 92% ORR reported in the PDAC cohort.
- Revenue Model: Confirm the timeline for potential future revenue, as the Gilead collaboration revenue stream has ceased and no product sales are expected in the near term.
- Stock Dilution: Review the impact of the June 2026 offering and remaining "at-the-market" (ATM) capacity ($35.6M) on shareholder dilution.